Nuwellis (NUWE) Set to Post Quarterly Earnings on Wednesday

Nuwellis (NASDAQ:NUWE) is expected to be posting its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of ($122.85) per share and revenue of $2.50 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:00 AM ET.

Nuwellis (NASDAQ:NUWE) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($239.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($214.20) by ($25.56). Nuwellis had a negative net margin of 123.38% and a negative return on equity of 623.14%. The firm had revenue of $1.97 million during the quarter, compared to analyst estimates of $2.42 million.

Nuwellis Stock Up 14.1%

NUWE opened at $5.91 on Wednesday. Nuwellis has a 12 month low of $2.52 and a 12 month high of $1,556.07. The company has a fifty day simple moving average of $6.46 and a 200 day simple moving average of $235.12. The stock has a market cap of $3.19 million, a P/E ratio of -0.00 and a beta of 0.03.

Analysts Set New Price Targets

A number of research firms have issued reports on NUWE. Weiss Ratings reissued a “sell (e+)” rating on shares of Nuwellis in a research note on Monday, September 21st. Wall Street Zen raised Nuwellis to a “hold” rating in a research report on Saturday, July 18th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

About Nuwellis

Nuwellis, Inc is a medical device company focused on fluid management therapies for patients with fluid overload. The company develops and commercializes ultrafiltration technologies designed to remove excess salt and fluid from the blood when conventional diuretic therapy may be inadequate or poorly tolerated.

Nuwellis’ principal product is the Aquadex system, including the Aquadex FlexFlow system, a compact ultrafiltration platform used in hospital settings. The system is intended for temporary extracorporeal fluid removal in patients with conditions such as fluid overload associated with heart failure, renal dysfunction, and other critical-care needs.